Sodium-Glucose Cotransporter-2 Inhibitors; cardiovascular outcomes; renal outcomes; empagliflozin; Dapagliflozin; diabetes; heart failure; chronic kidney disease. This evidence concerns the gene SLC5A2 and chronic kidney disease.